NEW YORK (GenomeWeb) – South Korea's Seegene has announced a joint venture in Mexico with Biodist Group to bring its PCR-based molecular diagnostics to the Latin American region.

Under the terms of the agreement, Seegene and Biodist will each hold a 50 percent stake in Biodist-Seegene Diagnostics. Seegene will license proprietary molecular diagnostics technologies and development expertise while Biodist will provide marketing and sales distribution.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.